Targeting the Renin-angiotensin-aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review.

IF 3.8 2区医学 Q2 ONCOLOGY Current Treatment Options in Oncology Pub Date : 2024-11-01 Epub Date: 2024-10-18 DOI:10.1007/s11864-024-01270-9

J Pawlonka, B Buchalska, K Buczma, H Borzuta, K Kamińska, A Cudnoch-Jędrzejewska

{"title":"Targeting the Renin-angiotensin-aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review.","authors":"J Pawlonka, B Buchalska, K Buczma, H Borzuta, K Kamińska, A Cudnoch-Jędrzejewska","doi":"10.1007/s11864-024-01270-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Opinion statement: </strong>The renin-angiotensin-aldosterone system (RAAS) is a crucial regulator of the cardiovascular system and a target for widely used therapeutic drugs. Dysregulation of RAAS, implicated in prevalent diseases like hypertension and heart failure, has recently gained attention in oncological contexts due to its role in tumor biology and cardiovascular toxicities (CVTs). Thus, RAAS inhibitors (RAASi) may be used as potential supplementary therapies in cancer treatment and CVT prevention. Oncological treatments have evolved significantly, impacting patient survival and safety profiles. However, they pose cardiovascular risks, necessitating strategies for mitigating adverse effects. The main drug classes used in oncology include anthracyclines, anti-HER2 therapies, immune checkpoint inhibitors (ICIs), and vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSPI). While effective against cancer, these drugs induce varying CVTs. RAASi adjunctive therapy shows promise in enhancing clinical outcomes and protecting the cardiovascular system. Understanding RAAS involvement in cancer and CVT can inform personalized treatment approaches and improve patient care.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"1406-1427"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11541340/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-024-01270-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Opinion statement: The renin-angiotensin-aldosterone system (RAAS) is a crucial regulator of the cardiovascular system and a target for widely used therapeutic drugs. Dysregulation of RAAS, implicated in prevalent diseases like hypertension and heart failure, has recently gained attention in oncological contexts due to its role in tumor biology and cardiovascular toxicities (CVTs). Thus, RAAS inhibitors (RAASi) may be used as potential supplementary therapies in cancer treatment and CVT prevention. Oncological treatments have evolved significantly, impacting patient survival and safety profiles. However, they pose cardiovascular risks, necessitating strategies for mitigating adverse effects. The main drug classes used in oncology include anthracyclines, anti-HER2 therapies, immune checkpoint inhibitors (ICIs), and vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSPI). While effective against cancer, these drugs induce varying CVTs. RAASi adjunctive therapy shows promise in enhancing clinical outcomes and protecting the cardiovascular system. Understanding RAAS involvement in cancer and CVT can inform personalized treatment approaches and improve patient care.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

以肾素-血管紧张素-醛固酮系统 (RAAS) 为靶点，保护心血管和提高肿瘤疗效：综述。

意见陈述：肾素-血管紧张素-醛固酮系统（RAAS）是心血管系统的重要调节器，也是广泛使用的治疗药物的靶点。RAAS 失调与高血压和心力衰竭等常见疾病有关，最近在肿瘤学领域也因其在肿瘤生物学和心血管毒性（CVTs）中的作用而备受关注。因此，RAAS 抑制剂（RAASi）可作为癌症治疗和心血管毒性反应预防的潜在辅助疗法。肿瘤治疗已取得重大进展，对患者的生存期和安全性产生了影响。然而，它们也会带来心血管风险，因此需要制定减轻不良反应的策略。肿瘤学中使用的主要药物类别包括蒽环类、抗 HER2 疗法、免疫检查点抑制剂（ICIs）和血管内皮生长因子（VEGF）信号通路抑制剂（VSPI）。这些药物在有效抗癌的同时，也会诱发不同的 CVT。RAASi 辅助疗法有望提高临床疗效并保护心血管系统。了解 RAAS 在癌症和 CVT 中的参与情况可为个性化治疗方法提供依据并改善患者护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.

期刊最新文献

"When Less is More": Paradigm Shifts in Radiation Treatment for Early-Stage Breast Cancer. Molecular Secrets Revealed: How Diabetes may be Paving the Way for Leukemia. New Therapeutic Targets in RAS Wild-type Pancreatic Cancer. Oligometastatic Breast Cancer: Seeking the Cure by Redefining Stage IV Disease? Community Palliative Care: What are the Best Models?